AME - Educational Analysis * US Equities
Educational Analysis * US Equities

AME

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerAME
CategoryEducational primer
Last reviewedNovember 2, 2026
You're viewing an older edition of this page.Read the latest edition →

Business Profile & Competitive Position

AMETEK, Inc. (AME) sits in the Industrials sector within the Electrical Equipment & Parts industry, but its business model is best understood as a global manufacturer of advanced electronic instruments and electromechanical devices. The company operates through two reportable segments: Electronic Instruments (EIG) and Electromechanical (EMG). EIG designs and manufactures analytical, test, and measurement instruments used across process, aerospace, power, and industrial applications, while EMG supplies precision motion control, thermal management, specialty metals, medical components, and electrical interconnects into aerospace and defense, medical, and automation markets.

The financial profile supports an asset-light, specialized-industrial narrative. AMETEK reports a net margin of 20.0% and a return on equity of 14.5%. A 20% net margin is unusually high for a diversified industrial hardware manufacturer and points to pricing power rooted in specialized instrumentation, entrenched customer relationships, and recurring aftermarket demand. The 14.5% ROE, while not extraordinary, is solid for a capital-goods business and is consistent with management’s stated objective of generating a “superior return on total capital.” Combined, these returns suggest that AMETEK’s portfolio sits above commodity-tier industrial exposure and closer to premium precision-equipment peers where brand, calibration, and regulatory certification matter.

Financial Posture

AMETEK carries a market capitalization of $56.1 billion and trades at a price-to-earnings ratio of 35.6. That multiple is materially above the historical range for broad industrials and signals that the market is already pricing in durable double-digit earnings growth. The profitability metrics—20.0% net margin and 14.5% ROE—help justify at least part of that premium, because they demonstrate conversion of revenue into profit and shareholder returns. With a beta of 0.97, the stock moves roughly in line with the overall market, so it is neither a defensive low-beta hiding place nor a high-beta cyclical proxy.

The tension in AMETEK’s financial posture is therefore valuation versus quality: the business generates strong margins and consistent returns, but the P/E of 35.6 embeds an expectation that current profitability can be sustained and expanded. Investors evaluating the stock need to weigh whether high-single-digit sales growth and double-digit EPS growth, which management targets under the AMETEK Growth Model, are sufficient to support the current multiple over a multi-year horizon.

Strategic Priorities & Outlook

In its most recent 10-K filing, AMETEK lays out a clear strategy centered on four operational pillars. First, the company is executing the AMETEK Growth Model, which targets high-single-digit annual sales growth, double-digit annual EPS growth, strong free cash flow generation, and a superior return on total capital. Second, it is pushing Operational Excellence through lean manufacturing, global sourcing, Design for Six Sigma, Value Engineering/Value Analysis, growth kaizens, digitalization, and artificial intelligence. Third, AMETEK is pursuing strategic acquisitions in adjacent or complementary markets aligned with secular growth themes; from 2021 through December 31, 2025, the company completed 15 acquisitions contributing roughly $1.8 billion in annualized sales. Fourth, the company continues to expand globally, maintaining best-cost manufacturing facilities in China, Czechia, Malaysia, Mexico, and Serbia to stay close to customers and to capture international demand.

Operationally, 2025 was a record year. AMETEK generated sales of $7,401.1 million, up 6.6% from 2024, and diluted EPS of $6.40, up 7.9%. The company also posted record operating income, net income, orders, and backlog. Acquisition activity was heavy: AMETEK deployed $933.2 million in cash, net of cash acquired, to buy Kern (high-precision machining and optical inspection solutions) and FARO Technologies (3D measurement and imaging solutions). Those deals widen the EIG and EMG technology portfolios and are consistent with management’s stated focus on precision measurement and advanced automation. Geographically, AMETEK remains an exporter of sorts: in 2025, 52% of EIG net sales and 42% of EMG net sales went to customers outside the United States.

Macro & Geopolitical Exposure

As an Electrical Equipment & Parts company with global manufacturing and a heavy aerospace, defense, medical, and industrial customer base, AMETEK sits at the intersection of several macro currents. Industrial capital spending is a primary demand driver: when process manufacturers, utilities, and automation OEMs cut capex budgets, demand for test-and-measurement instruments, motion-control systems, and thermal-management products softens. Aerospace and defense spending cycles matter because those end markets are large customers for both EIG and EMG products. Healthcare capital-equipment budgets influence the medical-components business, while automation and electric-vehicle manufacturing trends drive demand for precision motion control and electrical interconnects.

Trade policy and supply-chain geography are also relevant. With significant manufacturing footprints in China, Czechia, Malaysia, Mexico, and Serbia, and with roughly half of some segment sales going to non-U.S. customers, AMETEK is exposed to tariffs, export controls, freight costs, and currency translation. Regulations around product safety, defense contracting, medical-device standards, and environmental compliance can affect margins and go-to-market costs. In addition, input costs for specialty metals, semiconductors, and precision components can pressure gross margin if commodity or logistics inflation returns.

Recent Developments

Recent headlines have naturally clustered around the upcoming third-quarter 2026 report. On November 2, 2026, zacks.com published “AMETEK to Post Q3 Earnings: Time to Buy, Sell or Hold the Stock?” Two days earlier, on October 29, 2026, zacks.com ran “Unlocking Q3 Potential of Ametek (AME): Exploring Wall Street Estimates for Key Metrics.” On October 27, 2026, zacks.com asked “Ametek (AME) Earnings Expected to Grow: Should You Buy?” The same day, defenseworld.net reported that Citizens Financial Group Inc. RI purchased 5,502 shares of AMETEK. These articles emphasize the same question investors face heading into earnings: whether the company can continue its streak of growth.

The next scheduled earnings release is November 3, 2026, before the market open, with a consensus EPS estimate of $2.11. The stock is currently priced at $244.83, with an RSI of 49.2 and a 50-day exponential moving average of $244.82—essentially flat momentum heading into the print.

Earnings Behavior & Post-Earnings Drift

AMETEK’s earnings track record is remarkably consistent. Over the last eight reported quarters, the company has beaten estimates in all eight, for a 100% beat rate, with an average earnings surprise of 4%. If anything, the surprise distribution suggests AMETEK management and analysts tend to set guidance slightly conservatively, and actual results reliably clear that bar.

That beat rate, however, has not translated into a meaningful post-earnings drift. The average 5-day price move following the last eight reports is just 0.46%, classified as “flat.” In other words, the market tends to price in the beat rather than chase it. Looking at the most recent four quarters:

The pattern is absence of drift more than a directional trend. Beats are common, but the stock generally neither runs away nor sells off after results. For a company reporting on November 3, 2026 with a consensus EPS estimate of $2.11, the historical context implies the market’s real expectation may already be adjusted upward from the published estimate.

Frequently Asked Questions

How has AMETEK performed against Wall Street earnings estimates?

Over the last eight reported quarters, AMETEK has beaten earnings estimates in all eight, a 100% beat rate, with an average earnings surprise of 4%.

What are AMETEK’s main strategic focuses?

The company is focused on the AMETEK Growth Model, Operational Excellence initiatives, strategic acquisitions in adjacent markets, and global expansion via manufacturing in China, Czechia, Malaysia, Mexico, and Serbia.

When is AMETEK’s next earnings report?

AMETEK is scheduled to report on November 3, 2026, before the market open, with a consensus EPS estimate of $2.11.

For readers who want to go further than headline beat rates and valuation ratios, the full institutional verdict on AMETEK—including sell-side model updates, insider transaction context, and sector-relative rankings—is worth reviewing as a deeper dive into how the market is pricing this industrial compounder.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 2, 2026
AMETEK, Inc. · Industrials / Electrical Equipment & Parts
$56.1BMarket cap
35.6P/E
20.0%Net margin
14.5%ROE
100%Beat rate, last 8Q
4%Avg EPS surprise
0.46%Avg 5-day move after earnings
2026-11-03Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-08-04$2.09$1.99+5%+0.28%+0.89%
2026-04-30$1.97$1.9+3.7%-2.13%-0.33%
2026-02-03$2.01$1.94+3.6%-0.48%+1.83%
2025-10-30$1.89$1.76+7.4%+1.91%-0.54%
2025-07-31$1.78$1.69+5.3%--
2025-05-01$1.75$1.69+3.6%--

Previous AME editions

Beyond the primer

Get the institutional verdict on AME

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the AME verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.